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Aims Heart failure invariably affects patients with various forms of muscular dystrophy (MD), but the onset and molecular
sequelae of altered structure and function resulting from full-length dystrophin (Dp427) deficiency in MD heart tis-
sue are poorly understood. To better understand the role of dystrophin in cardiomyocyte development and the
earliest phase of Duchenne muscular dystrophy (DMD) cardiomyopathy, we studied human cardiomyocytes differ-
entiated from induced pluripotent stem cells (hiPSC-CMs) obtained from the urine of a DMD patient.
....................................................................................................................................................................................................
Methods
and results
The contractile properties of patient-specific hiPSC-CMs, with no detectable dystrophin (DMD-CMs with a dele-
tion of exon 50), were compared to CMs containing a CRISPR-Cas9 mediated deletion of a single G base at
position 263 of the dystrophin gene (c.263delG-CMs) isogenic to the parental line of hiPSC-CMs from a healthy in-
dividual. We hypothesized that the absence of a dystrophin-actin linkage would adversely affect myofibril and cardi-
omyocyte structure and function. Cardiomyocyte maturation was driven by culturing long-term (80–100 days) on a
nanopatterned surface, which resulted in hiPSC-CMs with adult-like dimensions and aligned myofibrils.
....................................................................................................................................................................................................
Conclusions Our data demonstrate that lack of Dp427 results in reduced myofibril contractile tension, slower relaxation kinet-
ics, and to Ca2þ handling abnormalities, similar to DMD cells, suggesting either retarded or altered maturation of
cardiomyocyte structures associated with these functions. This study offers new insights into the functional conse-
quences of Dp427 deficiency at an early stage of cardiomyocyte development in both patient-derived and CRISPR-
generated models of dystrophin deficiency.
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Introduction
Dilated cardiomyopathy and congestive heart failure are leading causes
of death in patients with Duchenne muscular dystrophy (DMD). In
young patients, DMD cardiomyopathy is characterized by initial diastolic
dysfunction and ventricular dilation leading to the onset of clinical mani-
festations.1 Therefore, there is considerable interest in determining the
pre-symptomatic aetiology and the downstream development of cardiac
abnormalities resulting from an absence of dystrophin in the heart.
* Corresponding authors. E-mail: dmack21@uw.edu (D.L.M.); E-mail: mregnier@uw.edu (M.R.)
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It is widely accepted that dystrophin deficiency results in increased cel-
lular vulnerability to mechanical stress during muscle contraction.
However, it is not known how this may affect the contractile apparatus
and, in turn, excitation–contraction (EC) coupling mechanisms of the
myocardium. Full-length dystrophin (Dp427) is strategically placed to
carry out mechanical roles, such as maintenance of membrane stability
and transduction of mechanical force from and to the extracellular ma-
trix, acting as a shock absorber to protect the sarcolemma. Dystrophin
also interacts with the dystrophin glycogen complex (DGC), which has
been shown to regulate signalling pathways involved in Ca2þ homeosta-
sis, mitochondrial function, motor protein interaction, and muscle-
specific gene expression.2 It has been proposed that a distinct pool of
dystrophin is co-localized with a-actinin and desmin at the Z-disks of
myofibrils in cardiac, but not in skeletal muscle.3 In addition, a short splice
variant of dystrophin (Dp71) expressed in cardiac muscle is specifically
located in transverse (T)-tubular membranes, though its role is not
clear.4
The absence of the damping role of Dp427 may negatively impact the
contractile apparatus and function of sarcomeres, the contractile units
that compose myofibrils, from a very early stage of development.
Observations of cardiac samples from DMD paediatric patients suggest
that lack of dystrophin may interfere with myofibril formation during de-
velopment.5 However, little is known about the role of dystrophin dur-
ing human cardiac development. Previous studies found dystrophin
expression on the surface of cardiomyocytes from 8-week-old foe-
tuses.6,7 Curiously, pre-myofibrils begin to assemble at the cell edges and
fuse at the level of the Z-bodies to form mature myofibrils that compose
the primitive contractile machinery of cardiomyocytes.8 From 8 to
24 weeks gestation dystrophin begins to distribute homogeneously,6 to-
gether with increased myofibril bundling, during the time when there is a
shift from a- to slow b-myosin heavy chain (MHC) in ventricular myo-
cardium.9,10 Although little information of this mechanism has been
reported for cardiac muscle, skeletal myotube fibre thickening is associ-
ated with increased density of dystrophin, together with downregulation
of foetal myosin and upregulation of adult myosin isoforms.6,11 At the Z-
disk level, costameree proteins connect Z-bands to T tubules and it is
here that dystrophin can transmit biomechanical stress through associ-
ated signalling proteins required for myofibril maturation.12
Cardiomyocytes from patients, generated from human cardiomyo-
cytes differentiated from induced pluripotent stem cells (hiPSC-CMs),
offer a limitless source of cells or cardiac tissue for modelling foetal de-
velopment of cardiomyopathies in vitro. We recently reported that
hiPSC-CMs benefit considerably from being cultured long term on
nanopatterned surfaces,13,14 with dramatic improvement of myofibril as-
sembly and alignment, together with preliminary formation of caveolae/
T-tubule-like profiles. However, myofibrils from these hiPSC-CMs still
have contractile properties very similar to what we recently reported
for myofibrils from foetal heart tissue of 12–14 weeks of gestational
age.10,14 Here, we report experiments using hiPSC-CMs generated from
the urine of a DMD patient with a total absence of dystrophin, due to a
deletion of exon 50 in the dystrophin gene (DMD-DExon50). To mini-
mize the impact of underlying genetic heterogeneity within patients, the
current study reports the creation of a Dp427 null allele by deleting a
single G base using the CRISPR-Cas9 enzyme (c.263delG) isogenic to a
healthy control. Compared to its parental isogenic control, the
c.263delG-cell line lacks expression of Dp427 but has low levels of a
shorter truncated dystrophin with complete deletion of the actin binding
domain (ABD). Thus, this represents a second cell line with full-length
dystrophin deficiency. Our data definitively demonstrate that the Dp427
null mutation alone impairs cardiomyocyte physiology. We previously
reported that at earlier stages cardiac differentiation, both DMD and
c.263delG cell lines consistently displayed unique features such as in-
creased membrane susceptibility to hypotonic stress, slower Ca2þ tran-
sients, and faster mitochondrial permeability pore opening time.13,15
In this study, we hypothesized that sarcomere dysfunction was a ma-
jor consequence of mechanical and structural changes caused by lack of
Dp427. We isolated myofibrils from DMD-hiPSC-CMs to study tension
generating capacity and the kinetics of activation and relaxation, using
our recently reported method.14 We identified contractile dysfunction
at the myofibril and single cell level for DMD-hiPSC-CMs compared with
control-hiPSC-CMs, and found similar results with the isogenic
(c.263delG) cell line generated from the control-hiPSCs. This demon-
strates directly that lack of full-length dystrophin alone is sufficient to
precipitate structural alterations and impact both myofibril function and
Ca2þ handling early in cardiomyocyte development. The results of this
and future investigations of contractile properties will help to dissect
mechanisms of the earliest stages of dystrophin deficiency that can lead
to MD cardiomyopathy and suggest interventions that could correct or
delay the cardiomyopathy at the pre-symptomatic stage.
Methods
An expanded version of the materials and methods appears in the
Supplementary material online that accompanies this manuscript. All authors
provided informed, written consent prior inclusion in the study.
Human pluripotent stem cell from urine and
cardiac differentiation
Protocols for this study were approved by the Institutional Review Board of
the University of Washington. Informed consent was given by patients prior
to the inclusion of people in the study. The isolation of the human cells and
the subsequent reprogramming into iPSC lines was performed conform the
declaration of Helsinki. Urine-derived cells from a healthy male donor (con-
trol UC3-4 A1) and a DMD patient with deletion of exon 50 in DMD gene
(UC72039) were reprogrammed into hiPSC lines as previously described.15
An isogenic control (c.263delG, UC1015-6) cell line was generated from con-
trol cell line by CRISPR-Cas9-mediated deletion of a single frame at the 50 of
Exon1 in DMD gene. Differentiated cardiomyocytes were obtained as de-
tailed in the Supplementary material online and matured long-term as single
cells on nanotopographic (nanopattern) substrata.14
Construction of Cas9/guide RNA-expressing
vectors
Guide sequences targeting the 30-end of the first muscle-specific exon of hu-
man dystrophin were designed using the CRISPR design tool (http://crispr.
mit.edu/) supported by the Zhang lab at MIT16 (see Supplementary material
online, Materials and methods section for full description). Functional valida-
tion of the guide sequences was carried out by transfecting HEK293 cells
with hSpCas9 (BB)-2A-Puro plasmids. The DNA dystrophin locus was PCR
amplified by PhusionVR High-Fidelity hot start II DNA Polymerase (Thermo,
Waltham, MA, USA) using primers shown in Supplementary material online.
Genome targeting and cell cloning
hSpCas9 (BB)-2A-Puro incorporated guide sequence 4 was chosen to trans-
fect normal male iPSCs (UC3-4) to generate the DMD-c.263delG cell line.
After Versene dissociation (Life Technologies), 3 106 UC3-4 iPSCs (gener-
ated from a normal donor) were transfected using the Neon Transfection
System (Life Technologies, CA, USA) following manufacturer’s instructions.
Genomic DNA of individual colonies was extracted for PCR amplification of
2 J. M. Pioner et al.
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the targeted dystrophin region. Mutation of the dystrophin locus was con-
firmed by sequencing and ion chromatogram (XIC) analysis (details in the
Supplementary material online).
Cell morphology, myofibril structural, and
protein analysis
Long-term cultured hiPSC-CM on nanopatterned surfaces were stained for
a-actinin, dystrophin, caveolin 3 (Cav3), and DAPI for morphological charac-
teristics and assessed by confocal microscopy. Myofibril structure was
assessed by transmission electron microscopy (TEM). Sarcomere protein
composition was studied by SDS-PAGE and western blot analysis using fro-
zen remains of myofibril preparations used for contractile assessments.
Details are provided in the Supplementary material online.
Myofibril mechanics
Myofibrils were isolated from DMD-hiPSC-CMs by a recently described cell
skinning and purification procedure.14 Myofibril mechanics, kinetics, and
Ca2þ sensitivity (pCa50) were measured by fast solution switching in a
custom-built apparatus described in previous publications.10,14,17–19 Details
are provided in the Supplementary material online.
Cell shortening and Ca2þ transients
Single hiPSC-CMs were visualized for fractional shortening using an inverted
microscope coupled to a video-based edge detection system with synchro-
nously detection of Fura-2 AM fluorescence for measuring intracellular Ca2þ
content. Cells were perfused at 37C with Tyrode solution and paced at 0.5,
1, or 2 Hz by field stimulation. Details are provided in the Supplementary ma-
terial online.
Statistical analysis
All data are reported in means ± SEM and were compared using a one-way,
two-way analysis of variance (ANOVA) with a Tukey post hoc test with statis-
tical significance set at P< 0.05* and P< 0.01** were applied for differences
in means between groups/conditions. For each analysis, n represented num-
ber of cells, myofibrils, or sarcomere determinants. Total number of cell dif-
ferentiation runs (N) used for this work were for Control N= 6, DMD N= 5,
c.263delG N= 3. The number of individual experiments (individual cover
slides) for each assessment was at least 3 from different differentiation runs.
Results
Human iPSC-derived cardiomyocytes
harbouring a single base pair deletion
(c.263delG) fail to express Dp427
Control-hiPSC (UC3-4 A1) and DMD-hiPSCs (UC72039 D3) were gen-
erated from urine-derived cells of a healthy volunteer and from a patient
carrying a deletion of exon 50 (DExon 50) in the dystrophin gene.15 To
create an isogenic hiPSC line, the dystrophin gene of a normal male iPSC
line was targeted by the CRISPR-Cas9 enzyme at the 50 coding region
within exon 1 of Dp427m (Figure 1A), the predominant dystrophin iso-
form of heart muscle. One clone revealed a deletion of guanine 263
(c.263delG) (Figure 1B), shifting the reading frame to prematurely termi-
nate dystrophin translation. To confirm that direct genomic manipulation
did not elicit undesirable chromosomal instability, the c.263delG clone
was re-examined for normal stem cell morphology, expression of
pluripotency-related markers (Supplementary material online, Figure
S1A), and a normal male karyotype (Supplementary material online,
Figure S1B).
The absence of dystrophin protein was measured by western blot
(Figure 1C, Supplementary material online, Figure S1C); antibodies against
the C-terminal domain of dystrophin to detect the 427 kDa dystrophin
protein in mutant cardiomyocytes, indicating that a full length
dystrophin-null may not have created by CRISPR-Cas9 methodology.
However, proteomic analysis by mass spectroscopy revealed a trun-
cated form of dystrophin with deletion of the N-terminal region up to
exon 6 corresponding to the actin-binding domain of full-length dystro-
phin. The full sequence analysis is reported in Supplementary material
online, Figure S2 and summarized in Figure 1D. The gel could not discern
the size difference between full-length and the truncated form (sche-
matic Figure 1D). The observed signal by ion chromatogram (XIC) analy-
sis of a peptide from the N-terminal region (LLDLLEGLTGQK), is visible
only in the healthy control (Supplementary material online, Figure S3A)
but absent in the c.263delG mutant (Supplementary material online,
Figure S3B–F) (Details in the Supplementary material online).
DMD-hiPSC-CM dimensions and myofibril
organization
Following cardiac differentiation with a monolayer directed protocol,20
15 days post-differentiated hiPSC-CMs were re-plated and cultured on
surfaces with 800 nm grooves/ridges (nanopatterns) for an additional
65–85 days (80–100 days total), as previously described.14 As described
below, long-term culture on nanopatterns that provided topographical
cues resulted in cardiomyocytes with morphological features much
more mature than those from our previous reports with these cells.
We compared the dimensions of DMD-CMs with those of control-
CMs in cells stained for Z-bands (anti a-actinin) (Supplementary material
online, Table S1). DMD-CMs had a significantly greater cell length (DMD:
140.23 ± 9.58lm vs. control: 116.91 ± 6.18lm, P< 0.05) and cell diame-
ter (DMD: 27.75± 0.93lm vs. control: 17.79± 0.62lm, P< 0.01),
resulting in a large increase in cross-sectional area (DMD: 13, 825 ± 2,
548 mm2 vs. control: 7, 696 ± 519 mm2, P< 0.01). The aspect ratio for
both groups was similar to adult cardiomyocytes and Z-disks were ob-
served across the entire cell width (diameter), suggesting DMD-CMs ex-
perienced hypertrophy and a greater number of myofibrils in parallel
(Figure 2A). Fluorescence antibody staining of a-actinin was used to visu-
alize Z-bands and the density and regularity of the transverse striation
patterns were analysed with fast Fourier transform (FFT) analysis
(Supplementary material online, Figure S4). The area of the first peak of
the power spectrum demonstrated that DMD-CMs had the same myofi-
bril alignment index as control-CMs (DMD: 0.018 ± 0.006 vs. control:
0.014± 0.002, P= 0.54). Resting sarcomere lengths were also not differ-
ent from control cells (SL, DMD: 1.93 ± 0.03 vs. control: 1.94 ± 0.11lm,
P= 0.88) and similar to values reported for adult cardiomyocytes,21 sug-
gesting no active crossbridge cycling at rest (Figure 2B). Thus, at the light
microscope level, myofibril and sarcomere organization did not appear
to be disrupted by a lack of dystrophin when cells received topographical
cues via long-term culture on nanopatterned surfaces.
Loss of Dp427 impairs myofibril mechanics
and kinetics in cardiomyocytes
We characterized the contractile properties of myofibrils isolated from
DMD cell lines for comparison with the control UC3-4 A1 cell line and a
second hiPSC-CM cell line reported in our recent work.14 Briefly,
hiPSC-CMs were chemically demembranated using rigor solution with
1% Triton to obtain single or small bundles (2-5 myofibrils per bundle).
The mechanical and kinetic properties of DMD- and control-myofibrils
were measured in a custom-built apparatus using fast solution switching
technique, as previously described.10,14,17 Figure 3A demonstrates that
Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes 3
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..DMD-CM myofibrils generated only about 30% of the tension pro-
duced by control myofibrils during maximal Ca2þ-activation (P< 0.01).
Average tension data for myofibrils from control- and DMD-CMs
(Figure 3B) are summarized in Table 1, and the data confirm significantly
lower tension production of DMD-CM myofibrils for both maximal
(pCa4.0, P< 0.01) and submaximal (pCa5.8, P< 0.05) Ca2þ activation.
The kinetics of activation (kACT) and the initial, slow phase of relaxa-
tion (slow kREL), both of which are dependent of crossbridge cycling and
detachment rates, did not differ between DMD- vs. control-CM myofi-
brils (Figure 3A and C, Table 1) at maximal activation (P= 0.78; P= 0.66,
respectively). However, for DMD-CM myofibrils the duration of the ini-
tial, slow phase (slow tREL) of relaxation was significantly prolonged
(P< 0.05, Table 1) and the fast phase of relaxation (fast kREL) was slower
(P< 0.05; Figure 2C; Table 1), resulting in significantly prolonged myofibril
relaxation. This occurred at all activating Ca2þ concentrations tested
(Figure 3D), suggesting prolongation of thin filament activation during
relaxation.22
The Ca2þ sensitivity of tension of control- (UC3-4 A1) and DMD-CM
myofibrils was determined by varying levels of activating Ca2þ (Figure
3E), and plots of the data fitted with the Hill equation allowed determina-
tion of pCa50 (the negative log Ca
2þ concentration at which tension is
half-maximal). In these pCa-tension plots (Figure 1E), pCa50 was greater
for DMD-CM myofibrils (6.15± 0.01, P< 0.05) than for control-CM
myofibrils (5.75 ± 0.08) (Figure 3F), indicating greater Ca2þ-sensitivity of
myofibril tension generation.
Ultrastructural organization and
sarcomeric protein expression of
DMD-hiPSC-CMs
To determine whether the above differences in contractile properties re-
sult from differing myofibril ultrastructure or sarcomere protein expression,
we performed the following analyses. CMs that were sparsely cultured
on nanopatterned surfaces were prepared for observation by TEM.
Figure 1 Creation of a dystrophin mutant human iPSC line with an isogenic background. (A) CRISPR-Cas9 enzyme was used to target the dystrophin
exon 1 in a normal iPSC line to create an isogenic dystrophin-modified line. (B) Sangers sequencing trace illustrates the location around the modified region
in both normal and modified hiPSC lines. The translated dystrophin N-terminus protein is shown at the top. (C) Cropped panel of antibody targeting C-ter-
minal domain of dystrophin in WT and mdx mouse cardiac tissue and control (UC3-4) and dystrophin mutant (c.263delG) hiPSC lines. Dystrophin bands at
427 kDa were detected in WT, control and, surprisingly, in c.263delG. Uncropped gel reported in Supplementary material online, Figure S1C. (D) Schematic
representation of Dp427 promoter for muscle, purkinje and brain to be consistent with Supplementary material online, Figure S2. Presumed mass spectros-
copy observable tryptic peptides are shown by black line segments (but were not detected in either cell line), peptides only seen in the normal UC3-4 hiPSC
cell line shown in green and those peptides present in both normal and UC-1015.6 hiPSC line (c.263delG) are shown in dark yellow.
4 J. M. Pioner et al.
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..High-magnification images (40 000) confirmed clearly aligned myofi-
bril Z-bands with widely spaced thick filaments likely forming bundles
(Figure 4A). Figure 4B summarizes a quantitative evaluation of sarco-
mere features of DMD- and control-CMs. Resting sarcomere length
measured from TEM images was shorter compared to measurements
obtained from confocal images for all cell lines, likely due to cell shrink-
age during the fixing process, but no difference was found between
DMD and control-CMs using either method (with TEM, SLDMD=
1.70 ± 0.02 vs. SLcontrol= 1.75 ± 0.02lm, P= 0.15). DMD-CM sarco-
meres had greater variability in structural organization. The percentage
of identifiable I-bands in sarcomeres per myofibril was significantly less
for DMD-CMs (IDMD = 36% ± 8% vs. Icontrol = 72% ± 7%, P< 0.05).
Also, sarcomere diameters (estimated from the length of Z-bands)
were significantly smaller (ZDMD = 485.58 ± 27.21 vs. Zcontrol =
645.98 ± 34.02 nm, P< 0.01), suggesting a possible reduction in the par-
allel assembly of myofilaments within individual myofibrils.
Furthermore, DMD A-bands were slightly shorter (ADMD =
1226.79 ± 31.82 vs. Acontrol = 1303.58 ± 24.76 nm, P< 0.05). H-zones
and M-lines were barely visible in any of the cell lines, not sufficient for
quantitative measurement and statistical analysis. Combined, these
data suggest that the ultrastructure of myofibrils is less developed in
DMD-CM sarcomeres. This likely contributes to the deficit in tension
production and, perhaps, slower relaxation.
We then examined sarcomere protein expression. Analysis was lim-
ited, due to the low amount of contractile material remaining from prep-
arations used for functional analysis, but western blots revealed that at
this time in culture (80–100 days post-differentiation) b-MHC was pre-
dominant and there was no detectable expression of a-MHC (Figure 3C).
This agrees with our recent report of hiPSC-CMs from a patient with a
MYH7 mutation and control cell lines for a similar time in culture on
nanopatterned surfaces.14 Also as in our previous report, we detected a
mixture of slow skeletal troponin I (ssTnI) and adult cardiac troponin I
(cTnI) that appeared to be similar for all cell lines. A quantitative analysis
of the ratio of ssTnI to cTnI is needed as there may be some difference
between the two cell lines (Figure 4C, Supplementary material online,
Figure S6) that may account for the greater Ca2þ sensitivity of force in
DMD CMs (Figure 3E). An important point to make is that cTnI composi-
tion is >_50% of total TnI. This is much greater than what has been
reported for most hiPSC-CM studies. The switch to b-myosin and pres-
ence of significant amounts of cTnI demonstrate maturation of all the
CM lines, and the similarities in their composition in myofibrils suggest
the lower tension production and slower relaxation kinetics are not
likely due to differences in these proteins.
Loss of Dp427 prolongs cardiac cell
contractility
To examine how dystrophin deficiency impacts intact cell contractile
properties, we measured fractional shortening and relaxation during
stimulated contractions using the IonOptix edge detection system at
37C in the presence of 1.8 mM extracellular Ca2þ (Figure 4A). Cells
were paced at 0.5, 1, and 2 Hz, while continuously perfused with Tyrode
solution. Fractional shortening at the peak of the twitch (expressed as
the percentage of variation from total diastolic cell length) is commonly
used as a parameter that reflects contractile capacity at low loads. The
fractional shortening of DMD-CMs was not significantly different from
control-CMs at any pacing frequency (Figure 4B). This would seem to
suggest no deficits in contractility at low load for dystrophin deficient
cells. However, the speed of unloaded contraction was reduced in both
DMD-DExon50 and c.263delG-CM lines. Cell shortening (time to peak
of contraction; DMD: P< 0.01, c.263delG: P< 0.01; Figure 4C) was slower
at 2 Hz and relaxation (time from peak contraction to 50% of relaxation
RT50; P< 0.01 for both cell lines; Figure 4D) was slower at all stimulation
frequencies. This indicates that both DMD-DExon50 and c.263delG cell
lines had distinctive prolonged contraction and relaxation after
Figure 2 DMD-CM dimensions, myofibril alignment and sarcomere length. Representative images of Control- and DMD-CMs stained for Z-bands (a-
actinin, red) and nuclei (DAPI, blue) for measuring cell dimensions and myofibril organization at 20 and 60 of magnification images of control- (A, B) and
DMD-CMs (C, D). Quantitative analysis are reported in the results: cellular cross section and cell diameter (ncontrol= 159, nDMD= 135); myofibril alignment
index (ncontrol= 20, nDMD= 30). Resting sarcomere length (SL) (ncontrol= 20, nDMD= 32, P= 0.88). P-value was estimated by one-way ANOVA with Tukey
post hoc test. N= 3 per cell line. Scale bars equal to 20mm for (A) and (C) and 40mm for (A), (D).
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long-term culture. Coupled with results from myofibril measurements,
we conclude that slower relaxation is at least partially due to properties
of the contractile apparatus. All cell lines had a low but residual popula-
tion of spontaneously beating cells that were excluded from this analysis
(Supplementary material online, Figure S4). Control-CMs had higher rate
of spontaneous beating than DMD-DExon50- and c.263delG-CMs
(58.5± 10.43 vs. 33.43 ± 4.28 vs. 35.4± 9.60 b.p.m. respectively, P< 0.05
by ANOVA) but had a lower number of spontaneous beating cells than
both DMD-DExon50- and c.263delG-CMs (8.8% vs. 20.6% vs. 17.2%, re-
spectively) (Supplementary material online, Figure S4), supporting the
idea that the absence of Dp427 may delay maturation of the excitation
contraction coupling.
Loss of Dp427 blunts cardiac contractile
reserve
To investigate the developmental state of the Ca2þ handling apparatus
and test the contractile reserve of intact DMD-CMs we used a post-rest
potentiation protocol.23 In adult cardiac muscle, a resting period intro-
duced during steady-state stimulated pacing enhances Ca2þ release from
the sarcoplasmic reticulum (SR) and potentiates contraction from the
first post-rest stimulation by multiple mechanisms. This includes in-
creased SR Ca2þ refilling and enhanced RyR2 channel availability, as a
consequence of recovery from inactivation/adaptation during the pro-
longed rest period. Rest periods of 5 s were introduced during 1 Hz stim-
ulation of control-, DMD-, and c.263delG-CMs, and the amplitude of the
Figure 3 Mechanical properties of myofibrils from DMD-CMs. Mechanical and kinetic properties of control- (UC3-4 A1) and DMD-CM myofibrils were
measured in a custom-built apparatus using fast solution switching. Compared to control-, DMD-CM myofibrils had (A, B) lower maximal (pCa4.0, represen-
tative traces) tension generating capacity. Kinetics of activation (kACT) and (C) relaxation (slow kREL) were analogous to control-CM myofibrils. A slower fast
phase of relaxation (fast kREL) with prolonged duration of slow phase of relaxation (slow tREL) correlated to Ca
2þ concentration in the (D) tREL slow/pCa
plot. (E) Percentage of tension was plotted against relative pCa level and the Hill equation was used to determine (F) myofibril Ca2þ sensitivity (pCa50). Data
for individual myofibrils are reported in Table 1; **P< 0.01 estimated by one-way ANOVA with Tukey post hoc test. N= 3 for each cell line. Number of
experiments control = 10 and DMD = 5, n, number of single myofibrils are reported in Table 1.
6 J. M. Pioner et al.
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post-rest potentiated contraction was plotted against that of the last reg-
ular contraction during pacing (Figure 5E). The relative amplitude of
post-rest twitches (p1/p2) was 25% less potentiated for DMD- and
c.263delG-CMs compared to control-CMs (P< 0.05 for both cell lines),
suggesting depressed contractile reserve that could result from Ca2þ
handling abnormalities (Figure 5F).
Loss of Dp427 alters cardiac Ca2þ transient
dynamics
We analysed intracellular Ca2þ transients of DMD- and c.263delG-CMs
(Figure 6) as these, together with myofibril function, determine the con-
tractile properties of cardiomyocytes. For these measurements it was
necessary to plate both control- and DMD-CMs on flat gelatine-coated
surfaces for simultaneous measures of Ca2þ transients and cell shorten-
ing, as the grooves in the nanopatterned surfaces produced light deflec-
tion phenomena that interfered with the fluorescent dye signal in our
system. Cells were loaded with Fura-2 AM and the fluorescent signal
that monitors intracellular Ca2þ was detected through excitation at
510 nm wavelength using a fluorescence detection system (IonOptix)
mounted on an inverted microscope. Representative traces are shown
in Figure 6A, B. There were no significant differences of baseline (resting)
Ca2þ or the maximal Ca2þ transient amplitude (Figure 6D–F), though
there did appear to be more variability in transient amplitudes for DMD-
CMs (Figure 6E). However, the kinetics of Ca2þ transients were signifi-
cantly impaired in DMD-CMs (Figure 5C). The transient rise from
baseline to 50% of the signal peak was similar for most stimulation proto-
cols, except for 0.5 Hz for DMD-CMs, where it was significantly slower
(P< 0.01). The time to the peak of the Ca2þ transient was significantly
prolonged for DMD-CMs, but not for c.263delG-CMs, at all stimulation
frequencies (Figure 6A,C). As a result, the shape of DMD-CM intracellular
Ca2þ transient rise at 0.5 Hz stimulation was biphasic, with an initial rapid
rise, followed by a slower phase to reach the peak (Figure 6A). While dif-
ferences in the rise of intracellular Ca2þ appeared to be minimal, the de-
cay of Ca2þ transients was greatly prolonged for both DMD-CMs and
c.263delG-CMs. The half time of Ca2þ transients decay (RT50; measured
as time from peak to 50% Ca2þ transient decay) was considerably longer
compared to control-CM at all pacing frequencies (Figure 6C). Taken
together, the combined results indicate that both cellular Ca2þ handling
and myofibril contractile abnormalities underlie the difference in con-
tractile properties seen in the DMD cell lines.
Dystrophin domains and costamere
formation in control cells
Finally, we investigated whether functional differences are associated
with differences in costamere formation and alignment with Z-bands
that occurs in normal cardiomyocyte development. Caveolin 3 (Cav3) is
a scaffolding protein that interacts with the dystrophin-associated glyco-
protein complex (DGC) and is involved in T-tubule formation in the stri-
ated muscle.24 We co-stained control- and DMD-CMs for Z-bands (anti
a-actinin) and caveolin 3 (anti-Cav3). DMD-CMs had negligible Cav3 lo-
calization within the sarcolemma (Supplementary material online, Figure
S6A) compared to control-CMs (control rcoloc = 0.37 ± 0.05 vs. DMD
rcoloc = 0.05± 0.04, P< 0.01) (Supplementary material online, Figure
S6B). Cav3 domains, identified with the help of 3D image reconstruction,
were rarely observed in DMD-CMs. This may suggest reduced ability for
caveolae/T-tubule formation in DMD-CMs, though this needs to be in-
vestigated further. We also used immunohistochemistry to evaluate dys-
trophin distribution (anti-dystrophin) and its association with Z-bands
(anti-a-actinin) of hiPSC-CMs cultured on nanopatterned surfaces
(Supplementary material online, Figure S7A, B). At 40 days post-differenti-
ation, 3D confocal images reconstruction of control-CMs displayed a
high level of dystrophin expression, forming an extensive network
throughout the cell volume (Figure 7A). No detectable Dp427 was ob-
served in DMD-DExon50- or c.263delG-CMs (Figures S2 and S3). Figure
7B shows the transverse plane (bottom view) and the sagittal plane (3D-
lateral view) of a 3D-control-CM (maximal cell height was
16.11 ± 1.25lm). For the cell membrane close to the nanopatterned
surface (bottom view), there was a transverse pattern of dystrophin that
formed clusters following the alignment of the nanogrooved substrate
along cell edges (Figure 7B, second panel). Throughout the entire cell sur-
face, aligned myofibrils were highly co-localized with dystrophin (rcoloc =
0.358± 0.02). Moreover, along the cell edges lateral distribution of dys-
trophin showed more marked signs of dystrophin clusters that tightly
juxtaposed Z-band domains with matching periodicity (dystrophin to
..............................................................................................................................................................................................................................
Table 1 Summary of mechanical and kinetic properties of myofibrils from hiPSC-CMs following maximal and submaximal
Ca2þ activation
Myofibril typea Tensiond kACT
e kREL, slow
f tREL, slow
g kREL, fast
h
mN/mm2 s1 s1 ms s1
pCa 4.0b
Control (n) 18.6 ± 2.5 (26) 0.51 ± 0.04 (23) 0.30 ± 0.04 (25) 192 ± 7.4 (29) 2.66 ± 0.3 (25)
DMD (n) 5.1 ± 0.5 (23)** 0.61 ± 0.09 (23) 0.32 ± 0.04 (26) 265 ± 10 (26)** 1.51 ± 0.2 (26)**
pCa 5.8c
Control (n) 8.5 ± 1.4 (22) 0.39 ± 0.06 (22) 0.30 ± 0.03 (17) 154 ± 7.9 (21) 2.47 ± 0.4 (22)
DMD (n) 4.0 ± 0.7 (17)* 0.34 ± 0.05 (17) 0.37 ± 0.06 (14) 265 ± 15 (14)** 1.09 ± 0.2 (15)**
aData are mean ± SEM. For the comparison with DMD myofibrils, control data set (merged UC3-4 A1 and control2 myofibrils) was used and refers to our recent work.
14 N= 3 for
each cell line. Number of experiments control = 10 and DMD = 5.
bMaximal activating solution.
cSubmaximal activating solution.
dTension, maximal, and submaximal Ca2þ-activated tension.
eRate of force generation following Ca2þ-activation.
fSlow, rate of the slow isometric phase of relaxation estimated from the normalized slope of the linear fit to the force trace.
gSlow, duration of the slow isometric phase of relaxation following sudden Ca2þ removal.
hFast, rate of the fast phase of relaxation estimated from the time constant of the exponential fit to the force trace.
*P< 0.05.
**P< 0.01; estimated by the Student’s t-test.
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dystrophin, DDlength = 1.91 ± 0.05mm vs. SL= 1.89± 0.04mm, P= 0.74),
suggesting increasing organization and stabilization of costameric
connections to myofibrils (Figure 7B, Supplementary material online,
Figure S7).
Discussion
Cardiac complications are a leading cause of morbidity and mortality in
DMD patients. Studies in animal models have provided some under-
standing, as they recreate some aspects of the human cardiac
phenotype.25 However, human dystrophin deficiency that leads to DMD
cardiomyopathy needs to be modelled to validate pathogenic mecha-
nisms and to identify disease-specific molecular targets that may be ame-
nable to therapeutic intervention. Patient-derived and CRISPR-Cas9
edited hiPSC-CMs offer a cell level model to study the early-stages of hu-
man DMD cardiomyopathy, as opposed to the latter stages of the dis-
ease. Our stem cell to cardiomyocyte differentiation and culturing
protocol may recapitulate critical developmental steps in the cardiac lin-
eage, thus allowing us to observe the first molecular, structural, and func-
tional consequences downstream of full-length dystrophin (Dp427m)
deficiency (Figure 8). A single base in exon 1 in DMD gene was deleted
Figure 4 Sarcomere composition of DMD-hiPSC-CMs. Single DMD-(hiPSC)-CMs sparsely cultured on nanopatterned surfaces at 100 days post differen-
tiation. (A) Transmission electron microscopy (TEM) at high magnification (40 000) showed aligned Z-bands (black arrowheads). (B) Observations of
DMD resting sarcomere length (SL; black dotted two-headed arrow), I-bands per sarcomere (%), Z-band width (cross sectional length; black solid two-
headed arrow) and A-band length (black dashed two-headed arrow). (C) Sarcomere protein expression of DMD-CMs were compared to control-CMs, foe-
tal left ventricular (LV) samples (130 gestational days) and adult human and rat LV. The lower panels demonstrate detection of a- and b-MHC (top), cTnI,
and ssTnI from a single gel. Single panels are cropped image from the same gels. Uncropped images are shown in Supplementary material online, Figure S6.
N= 3 for each cell line, n of sarcomeres was 56–62 per cell line for a total of three individual experiments. Scale bars equal to 500 nm. Average are reported
as means ± SEM; **P< 0.01; *P < 0.05; NS, not significant; estimated by one-way ANOVA with Tukey post hoc test.
8 J. M. Pioner et al.
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(c.263delG) and Dp427m was not detected in the isogenic cardiomyo-
cytes. We found expression of a truncated dystrophin, likely due to the
presence of a promoter in exon 6. However, our results demonstrate
that c.263delG cardiomyocytes mirror DMD patient cardiomyocytes
(Supplementary material online, Table S2), strongly suggesting that
the truncated dystrophin lacking of the N-terminal actin-binding domain
(Exons 1–5) does not provide stability as the Dp427. This demonstrated
that absence of full-length dystrophin alone is sufficient to cause
development of dysfunctional differences that are likely a factor in devel-
opment of the cardiac disease phenotype. We have provided an in depth
analysis of isolated myofibril contractile mechanics and kinetics and the
Ca2þ handling properties of DMD-CMs, and identified structural
and protein correlates that may be responsible for differences from con-
trol-CMs.
The morphology of DMD- and control hiPSC-CMs (Figure 2) in this
study was matured (cultured for 80-100 days) far beyond previous
reports for the same cell lines, which were grown on nanopatterned sur-
faces for less than 35 days.13,15 Longer culturing in the current study has
significant advantages for the identification of biophysical alterations that
occur early in development and dissection of the pathophysiological
mechanisms associated with the disease. DMD-CMs in this study dis-
played prominent cell hypertrophy that could be a normal outcome of
the maturation process, but also may be a compensatory mechanism in
response to impaired contractile properties, as discussed below. This
also occurred with less mature DMD-CMs (of the same cell line) grown
on the same nanopatterned surfaces,13 but longer culturing resulted in
much larger cells and a greater hypertrophy in DMD compared with
control cells. Importantly, both DMD and control cell lines displayed
Figure 5 Intact cell contractility of DMD-CMs. Intact cell contractility was measured on flat surfaces (80 days p.d.) for simultaneous detection of Ca2þ
transients (Figure 6) at 37C and 1.8 mM external Ca2þ. DMD-CMs were compared with control- and c.263delG-CMs at three different pacing frequencies
(0.5, 1, 2 Hz). (A) Representative traces of control-, DMD-, and c.263delG-CMs showed (B) preserved cell contractility (% of fractional shortening) at any
pacing frequency, (C) slower time to peak of contraction at 2 Hz, and (D) slower relaxation kinetic (RT50%) at all frequencies. For cell contractility analysis
N= 5 for control and DMD and N= 3 for c.263delG, n= 18–20 for each cell line for a total of five individual experiments. (E) A post-rest potentiation proto-
col was employed at 1 Hz, with a resting pause of 5 s in each cell line. The potentiation is estimated by p1/p0 (peak amplitude post-rest/before rest), bl, base-
line. (F) Both DMD- and c.263delG-CMs had depressed potentiation of contraction (n= 11–13 per cell line); n is the number of cells. Average are reported
as means ± SEM; **P< 0.01; *P < 0.05; NS, not significant; estimated by two-way ANOVA with Tukey post hoc test.
Absence of full-length dystrophin impairs normal maturation and contraction of cardiomyocytes 9
D
ow
nloaded from
 https://academ
ic.oup.com
/cardiovascres/advance-article-abstract/doi/10.1093/cvr/cvz109/5482575 by U
N
IVER
SITA D
I FIR
EN
ZE D
IPAR
TIM
EN
TO
 D
I PED
IATR
IA user on 08 January 2020
..
..
..
..
..
..
..
..
..
..
..
..similar myofibril alignment and resting sarcomere length. This result con-
trasts with previous findings for less mature DMD-CMs and a hiPSC-CM
cell line carrying a dilated cardiomyopathy-associated mutation13,26 on
flat surfaces, both of which impair myofibril alignment in the diseased
cells. This suggests in absence of Dp427, myofibrils may be less able to
organize or bundle in the absence of strong external, topographical cues
and are more susceptible to disorganization under stress. It also supports
the idea that disease-causing mutations can precipitate physiological
defects early in cardiac lineage commitment, but some aspects of the dis-
ease pathology require further maturation and/or in vitro aging for full
manifestation of the disease phenotype.
To establish a linkage between dystrophin and sarcomeres, both dys-
trophin and a-actinin (Z-bands) were labelled in control-hiPSC-CMs.
We confirmed that early in post-differentiated hiPSC-CMs, dystrophin is
uniformly distributed in a wide network. At cell edges dystrophin
domains appeared in line with Z-bands with matching periodicity. This is
Figure 6 Ca2þ handling abnormalities of DMD–CMs. Ca2þ transient measurements of control-, DMD-DExon50 and c.263delG-CMs detected by Fura-
2AM fluorescent dye. (A) Representative traces (0.5 Hz) were normalized to show Ca2þ transient kinetics. (B) Control- (representative), DMD- and
c.263delG-CMs were paced at three different frequencies (0.5, 1, 2 Hz). (C) Slower Ca2þ transient decay of DMD- and c.263delG-CMs at any frequency. (D)
Representative Ca2þ transients of control-, DMD- and c.263delG-CMs (0.5 Hz). (E) The frequency count for DMD-DExon50 exhibited variable Ca2þ tran-
sient amplitudes (F340/F380) within the population, while c.263delG had a Gaussian distribution similarly to control-CMs. (F) Similar distribution of Ca
2þ tran-
sient baseline. Both distributions are shown at 0.5 Hz but were also variable at the other frequencies (data not shown). The distribution of the values in the
frequency count were confident within the cell lines. For Ca2þ transient analysis N= 5 for control and DMD and N= 3 for c.263delG, n= 37–52 per cell line
for a total of five individual experiments. Average are reported as means ± SEM; **P< 0.01; *P< 0.05; NS, not significant; estimated by two-way ANOVA
with Tukey post hoc test.
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..similar to previous observations in wild-type mice,27 suggesting co-
dependence in forming costameric regions. These findings also support
the idea that costameres are hotspots during early stages of hiPSC-CM
maturation, similar to human foetal ventricular tissue.7 Since myofibrils
were aligned in both control and DMD-cell lines, it also suggests that re-
duction or loss of costamere formation may affect the development of
the contractile apparatus.
Our custom-built apparatus for isolated myofibril preparations allows
evaluation of isolated myofibril mechanics and kinetics of activation and
relaxation, independent of the Ca2þ handling system of hiPSC-CMs.14
We were initially surprised to find much weaker myofibril tension gener-
ating capacity for myofibrils from dystrophin-deficient CMs, as dystro-
phin is not a sarcomere protein. However, the kinetics of tension
development (kACT) and the early phase of relaxation (slow kREL), which
reflect the properties of the isovolumetric phase of systole and early
phase diastole in hearts (respectively), were not different compared to
myofibrils from control-CMs. This suggests similar acto-myosin cycling
kinetics that is likely reflective of the predominant expression of the
b-MHC isoform in both DMD- and control-CMs at this stage of matura-
tion. It also parallels what we found for developing foetal ventricular
myocardium, where the switch from a- to b-MHC isoform occurs very
early (within two months) in human ventricular myocardial develop-
ment.9,10 Our finding that average Z-band diameters of individual myofi-
brils were significantly smaller for DMD-CMs suggests myofibril
assembly may be impacted by the lack of full-length dystrophin. It is pos-
sible that defects in the mechano-transduction signals between DGC
and Z-bands could result from a lack of Dp427m, and this may interfere
with correct myofibril formation and organization.3 Interacting proteins
Figure 7 Myofibril alignment and dystrophin network during nanopatterned-mediated maturation. Confocal images of control-(hiPSC)-CMs cultured on
the nanogrooved substrates. (A) Control-CMs were stained with antibodies against Z-bands (a-actinin, red), dystrophin (green) and nuclei (DAPI, blue).
Representative 3D reconstructions showed clear myofibril alignment quantified by fast Fourier transform (FFT) analysis. Dystrophin network formation oc-
curred early (40 p.d. days) and covered the entire sarcolemma. (B) The bottom view of a hiPSC-CM showed dystrophin distribution (green) in a bi-dimen-
sional view (a). The yellow-outlined blow-up shows an area of cell edge with dystrophin clusters and the same periodicity of Z-bands (a). Black and white
panels show single staining of dystrophin (b), a-actinin (c), and DAPI (d). Dystrophin domains juxtaposed a-actinin staining (white arrowhead, left panel). For
this analysis, the number of 3D-cell reconstruction was 12. Scale bars equal to 20mm. One-way ANOVA with Tukey post hoc test.
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of costameres/Z-bands are in a well-suited location to influence correct
myofibrillogenesis.12 The lower tension in DMD-CM myofibrils is most
easily explained by delayed or abnormal maturation of sarcomere ultra-
structure (Figure 3B) or by reduced myosin density within the sarcomere
that could reduce cross-bridge binding during contraction. In support of
this idea, previous studies with DMD-hiPSC-CMs report a reduced tran-
scription profile of sarcomere genes28 and reduced sarcomere actin
turnover.13 Therefore, the hypertrophic response in DMD-hiPSC-CMs
reported in this and our previous study 13 may well be a mechanism to
compensate for weaker tension generating capacity of individual myofi-
brils. Of note, external environmental conditions (i.e. nanotopography)
may play a major role in exacerbating the DMD-hiPSC-CM phenotype,
but cell morphology may adapt differently in vivo during DMD cardiomy-
opathy progression.
Another potential compensatory mechanism is the greater Ca2þ sen-
sitivity (pCa50) of tension development for myofibrils from DMD-hiPSC-
CMs, which could result from differences in thin filament protein isoform
expression or phosphorylation patterns. An in depth proteomic analysis
was beyond the scope of our current study, due to the low density of
cells on nanopatterned surfaces (by design, to ensure individual cells)
and the length of the culture period (80–100 days). Because of this, we
felt it was important to focus on contractile properties for this report,
and this limited the amount of contractile material available for protein
analysis. The prolonged relaxation of myofibrils from DMD-hiPSC-CMs,
even though myosin isoform did not differ from control hiPSC-CM
myofibrils, may indicate slower Ca2þ dissociation from troponin in
DMD-CM myofibrils, an idea supported by the increased pCa50 (myofi-
bril Ca2þ sensitivity).22,29 Indeed, we have demonstrated that slower tro-
ponin kOFF can slow myofibril relaxation, prolonging the early, slow
phase of relaxation (tREL) and the larger, fast component of relaxation
(fast kREL).
22 The small amount of protein available following myofibril
mechanical experiments was not sufficient to establish whether there
were differences in the amount of the adult cardiac form of troponin I
(cTnI) vs. the embryonic isoform slow skeletal (ssTnI) incorporated into
myofibrils, or other post-translational modifications (e.g. phosphoryla-
tions), both of which could impact the Ca2þ binding properties of tropo-
nin.10,30 However, our ultrastructural analysis suggests that lack of
Dp427 may influence the rate of sarcomere structure maturation even if
protein isoform expression patterns are similar, and this may compro-
mise the contractile properties of single myofibrils.
Another limitation of this work was the inability to measure Ca2þ
transient behaviour from cells on nanopatterns, due to the reflective
properties of the grooves in the surface. This necessitated measuring
Ca2þ transient behaviour under a different culture condition (flat matrix
surfaces). In previous experiments myofibrils from hiPSC-CMs cells cul-
tured on gelatin-coated surfaces were less aligned and dense,13 though
we have demonstrated that long-term culture can reduce this shortcom-
ing.31 Interestingly, the magnitude of contraction (cell fractional shorten-
ing) of DMD-DExon50- and c.263delG-CMs was similar to controls. This
may be due in part to the apparent increase in myofibril Ca2þ sensitivity
and/or longer Ca2þ transient duration. Additionally, measurements of
contraction in culture are done at low load, which can mask contractile
Figure 8 Schematic representation of loss of Dp427 consequences in hiPSC-CMs. Consequences of the altered genotype (loss of Dp427) on phenotypic
adaptions include structural-functional alterations in DMD-hiPSC-CMs (orange/yellow-green panel respectively). Deficit of caveoloe formation may slow
down Ca2þ transients and maintain more dependence to sarcolemmal Ca2þ entry. On the other side, impaired maturation of specific sarcomere determi-
nants may result in weaker myofibril tension production. Increased Ca2þ-sensitivity of tension development and cellular hypertrophy may potentially rescue
cell contractility at low load. Slower Ca2þ transient kinetics and myofibril relaxation are likely a main cause of slower cell contractility. Dashed lines refer to
hypothetic mechanisms to explore. Colourful progress bars (Days 0 to 100 from cardiac differentiation) refer to findings of this work and previous studies
on these DMD-hiPSC-CM lines.13,15
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deficits associated with reduced tension producing capacity during con-
traction. An additional possible consequence of the lack of Dp427 during
hiPSC-CM maturation in culture may be mitochondrial damage, due to
oxidative stress. This has often been reported as a leading factor in the
pathogenesis of DMD, and early-stage DMD-hiPSC-CMs from the pa-
tient with exon 50 deletion had faster mitochondrial permeability pore
open,15 which was confirmed in a study by Lin and colleagues.28 Altered
mitochondrial ATP production may influence the energy available for
contraction and Ca2þ cycling, affecting SERCA pump activity that
restores Ca2þ to the SR. In addition, nitric oxide synthase (NOS)-in-
duced ROS and subsequent genomic instability were reported to be
close connected to loss of dystrophin in hiPSCs.32 Oxidative stress may
also cause irreversible post-translational modifications on myofibril for-
mation and/or function via carboxylation, glutathionylation or nitrosyla-
tion of amino acid residues. This may have contributed to lower force
production in DMD myofibrils and perhaps the prolongation of the early,
slow phase of relaxation (tREL, slow) that is modulated by thin filament de-
activation rates.22
In support of these findings, twitch amplitude was blunted under ino-
tropic intervention, measured as post-rest contractions, due to reduced
contractile reserve in DMD-CMs. This can be explained by Ca2þ han-
dling abnormalities, possibly related to alteration of SR regulation, matu-
ration or volume. Altered Ca2þ handling is considered a hallmark due to
loss of Dp427 in several models.2 DMD-CMs have slower Ca2þ tran-
sient decay in the early stage post differentiation15 and here we found
that this increased as DMD-CMs age. The difference in RT50 of Ca2þ
transient decay could result from slower Ca2þ refilling on the SR by
SERCA pumps and/or slower Ca2þ extrusion from the Na2þ/Ca2þ ex-
changer (NCX). Studies in mdx mice suggest a myriad of mechanisms for
altered Ca2þ handling in cardiac muscle,2,33 thus future studies should
explore pathways regulating the Ca2þ handling abnormalities of DMD-
CMs. For instance, within DGC-associated proteins, Cav3 is a scaffolding
protein localized at the opening of caveolae and T tubules, responsible
for their formation and provides stability to the muscle cell mem-
brane.34,35 Not least, Cav3 upregulation progressively clusters with
HCN4 (If current) and is correlated by decreased spontaneous beating
rate in later stages post differentiation of hESC-CMs.36,37 As reported
for adult mdx mice,38 a deficit or delayed formation of T-tubules in
DMD-CMs may be a specific disorder of DMD cardiomyopathy, since
we previously observed a relatively strong presence of Cav3 profiles in a
hiPSC-CM model of familial cardiomyopathy that have similar deficits in
myofibril contraction strength.14 Absence of Dp427 may lead to aber-
rant caveolae or T-tubule-like architecture and alter the signalling path-
ways of costameric proteins, limiting the maturation process of single
sarcomeres. However, the current study provided only cursory evi-
dence for this, and further studies are needed to draw any conclusions
regarding this mechanism.
Translational implications and study
limitations
It has long been thought that clinical manifestations of DMD cardiomy-
opathy were predominantly a secondary effect due to a state of deterio-
ration that progresses as DMD patients age.39 Despite pathogenesis
being apparent during foetal striated muscle cell development40 and sim-
ilar mechanisms that are primarily related to Ca2þ homeostasis,25 in vivo
studies on mdx mice suggested that the cardiomyopathy may be inde-
pendent of skeletal muscle disease.41 While there may certainly be some
variance in cell lines derived from different DMD patients, due to
epigenetic and other factors, use of single gene editing to create an iso-
genic pair of full-length dystrophin knockout and control cell lines is a rig-
orous means of testing the role of an individual protein.42 However, a
complete dystrophin knockout or more cell lines with similar exon
mutations would be required for creating and studying DMD. In the pre-
sent work, the similar results between the patient and the CRISPR-Cas9-
edited cell lines provide direct evidence that the lack of Dp427 directly
affects cardiomyocyte function, and the cardiomyopathy is not a second-
ary remodelling due to systemic alterations (i.e. airway obstruction).
Our findings demonstrate that Dp427 deficiency results in delayed or ab-
normal maturation of cardiomyocyte structure and function, which may
resemble some developmental aspects of DMD cardiomyopathy that
manifest in the young human adult.1,43 Echocardiographic findings44 and
left ventricular tonic contraction (LV TC, or underfilling) 45 in DMD
patients have demonstrated evidence of diastolic dysfunction in the early
stages preceding the development of heart failure, systolic ventricular
dysfunction, or dilated cardiomyopathy.
We believe that hiPSC-CMs can provide a platform to investigate the
earliest stages of disease development. However, while the structure/
function abnormalities found in hiPSC-CMs can recapitulate aspects of
the dystrophic cardiomyopathy, these mechanisms may not necessarily
appear in the human heart until birth, which is conditioned by different
loading conditions (i.e. cardiac hypertrophy). In addition, early respira-
tory involvement and loss of ambulation may distinctly aggravate the car-
diac phenotype during the paediatric age.
DMD cardiomyopathy is still treated with the classical therapy for
heart failure1 and clinical observations suggest that a pharmacological
prophylaxis can effectively reduce the occurrence of dilated cardiomy-
opathy within the paediatric age range.45 Therefore, the DMD-CM plat-
form presented here could be used as a model to discover and test
novel therapies targeted at halting heart disease progression in DMD.
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